Literature DB >> 15126693

Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans.

J Alex Parker1, Sébastien Holbert, Emmanuel Lambert, Salima Abderrahmane, Christian Néri.   

Abstract

The identification of disease genes for several neurodegenerative illnesses has allowed for the development of disease models in experimental organisms. We discuss our approach to studying Huntington's disease, the best characterized of the polyglutamine (polyQ) expansion disorders. We have developed a system in Caenorhabditis elegans to study the effects of (polyQ)-dependent neuronal dysfunction at the resolution of two neurons in screening for genetic and pharmacological suppression. Our data suggest that C. elegans might be instructive in searching for targets and active compounds against polyglutamine neuronal toxicity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15126693     DOI： 10.1385/JMN:23:1-2:061

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  63 in total

1.  New light on polyglutamine neurodegenerative disorders: interference with transcription.

Authors:  C Néri
Journal:  Trends Mol Med       Date:  2001-07       Impact factor: 11.951

2.  Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA.

Authors:  Jill Heemskerk; Allan J Tobin; Lisa J Bain
Journal:  Trends Neurosci       Date:  2002-10       Impact factor: 13.837

3.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats.

Authors:  M F Perutz; A H Windle
Journal:  Nature       Date:  2001-07-12       Impact factor: 49.962

4.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

5.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

Review 6.  Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches.

Authors:  C L Wellington; M R Hayden
Journal:  Clin Genet       Date:  2000-01       Impact factor: 4.438

7.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

Review 8.  Lessons from animal models of Huntington's disease.

Authors:  David C Rubinsztein
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

9.  Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain.

Authors:  J D Wood; J C MacMillan; P S Harper; P R Lowenstein; A L Jones
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

10.  Combinatorial control of touch receptor neuron expression in Caenorhabditis elegans.

Authors:  S Mitani; H Du; D H Hall; M Driscoll; M Chalfie
Journal:  Development       Date:  1993-11       Impact factor: 6.868
View more
  5 in total

1.  Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans.

Authors:  Kayalvizhi Madhivanan; Erin R Greiner; Miguel Alves-Ferreira; David Soriano-Castell; Nirvan Rouzbeh; Carlos A Aguirre; Johan F Paulsson; Justin Chapman; Xin Jiang; Felicia K Ooi; Carolina Lemos; Andrew Dillin; Veena Prahlad; Jeffery W Kelly; Sandra E Encalada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

2.  The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease.

Authors:  Francesca Farina; Emmanuel Lambert; Lucie Commeau; François-Xavier Lejeune; Nathalie Roudier; Cosima Fonte; J Alex Parker; Jacques Boddaert; Marc Verny; Etienne-Emile Baulieu; Christian Neri
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

3.  Beneficial effect of Xuebijing against Pseudomonas aeruginosa infection in Caenorhabditis elegans.

Authors:  Le Zhang; Yuxing Wang; Chang Cao; Yike Zhu; Wei Huang; Yi Yang; Haibo Qiu; Songqiao Liu; Dayong Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

4.  Huntington's disease: the case for genetic modifiers.

Authors:  James F Gusella; Marcy E MacDonald
Journal:  Genome Med       Date:  2009-08-21       Impact factor: 11.117

5.  Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.

Authors:  Yixuan Zeng; Wenyuan Guo; Guangqing Xu; Qinmei Wang; Luyang Feng; Simei Long; Fengyin Liang; Yi Huang; Xilin Lu; Shichang Li; Jiebin Zhou; Jean-Marc Burgunder; Jiyan Pang; Zhong Pei
Journal:  Drug Des Devel Ther       Date:  2016-04-13       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.